What is Amferia?
Amferia is a biotechnology firm focused on combating bacterial infections, including those resistant to conventional treatments. The company's core innovation is an antimicrobial amphiphilic hydrogel, developed through extensive research in collaboration with Chalmers University of Technology. This advanced material demonstrates efficacy against bacteria while maintaining biocompatibility. The initial product derived from this technology platform is a specialized wound-care dressing designed for dry-to-low exuding wounds, addressing a critical need in the medical device market.
How much funding has Amferia raised?
Amferia has raised a total of $1.3M across 1 funding round:
Other Financing Round
$1.3M
Other Financing Round (2024): $1.3M, investors not publicly disclosed
What's next for Amferia?
The substantial enterprise-level funding and strategic investment signal Amferia's transition into a scaling phase. This capital infusion is expected to accelerate product development, expand market penetration for its wound-care solutions, and potentially fund further research into new applications of its hydrogel technology. The company's focus on tackling antibiotic resistance positions it strategically within the growing global healthcare market, aiming to establish itself as a leader in advanced antimicrobial materials.
See full Amferia company page
